

	Full Name	HCPs: City of Principal Practice HCOs: city where registered	Country of Principal Practice	Principal Practice Address	Unique country identifier (optional*)	Donations and Grants to HCOs	Contribution to costs of Events			Fee for service and consultancy		TOTAL	
							Sponsorship agreements with HCOs / third parties appointed by HCOs to manage an Event	Registration Fees	Travel & Accommoda tion	Fees	Related expenses agreed in the contract, including travel & accommodati on relevant to the contract		
HCPs	INDIVIDUAL NAMED DISCLOSURE - one line per HCP (i.e. all transfers of value [ToVs]/annum for an individual HCP will be summed up: itemization should be available for the individual Recipient or public authorities' consultation only)												
	Dr. Alan David Irvine	Dublin	Ireland	St. James Private Clinic St. James Hospital Dublin 8 Ireland	115037	N/A	N/A	N/A	N/A	2983.3	335.54	3318.84	
	Dr. Martin Steinhoff	Dublin	Ireland	9 Rosemount Crescent Clonskeagh Dublin 4 Ireland	410583	N/A	N/A	N/A	N/A	2128.66	966.56	3095.22	
	OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons												
	Aggregate amount attributable to transfers of value to such Recipients						N/A	N/A					
	Number of Recipients in aggregate disclosure						N/A	N/A					
	Of the total number of Recipients whose ToV was disclosed % disclosed in aggregate						N/A	N/A					
HCOs	INDIVIDUAL NAMED DISCLOSURE - one line per HCO (i.e. all ToVs /annum for an individual HCO will be summed up: itemization should be available for the individual Recipient or public authorities' consultation only)												
	HCO 1				N/A	annual amount	annual amount	annual amount	annual amount	annual amount	annual amount	Optional	
	etc				N/A	annual amount	annual amount	annual amount	annual amount	annual amount	annual amount	Optional	
	OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons												
	Aggregate amount attributable to transfers of value to such Recipients						Aggregate HCOs	Aggregate HCOs	Aggregate HCOs	Aggregate HCOs	Aggregate HCOs	Aggregate HCOs	Optional
	Number of Recipients in aggregate disclosure						number	number	number	number	number	number	Optional
Of the total number of Recipients whose ToV was disclosed % disclosed in aggregate						%	%	%	%	%	%	N/A	
R&D	AGGREGATE DISCLOSURE												
	Research & Development Transfers of Value											N/A	

* To uniquely identify HCPs the use of the relevant Medical Council/Pharmaceutical Society of Ireland/Nursing and Midwifery Board of Ireland/Dental Council of Ireland registration numbers are strongly recommended.

N/A: not applicable. HCP: healthcare professional. HCO: healthcare organisation

Regeneron Ireland Methodological Disclosure Note

Purpose:

The purpose of this document is to summarize the methodologies used in preparing the disclosure of transfers of value to Healthcare Professionals (HCP) and Healthcare Organizations (HCO) as required in Annex V of the IPHA Code of Practice for the Pharmaceutical Industry.

Background:

Regeneron Ireland, a wholly owned subsidiary of Regeneron Pharmaceuticals, Inc., has signed the IPHA Code of Practice for the Pharmaceutical Industry. Regeneron Ireland must report all transfers of value occurring within Ireland and to Irish HCPs and HCOs, whether such transfers of value come from Regeneron Ireland or any other Regeneron entity.

Definitions:

Healthcare Professional (HCP): as any registered medical practitioner, registered dentist, registered pharmacist or registered nurse.

Healthcare Organization (HCO): any healthcare, medical or scientific association or organization (irrespective of the legal or organizational form) such as a hospital, clinic, foundation, university or other teaching institution or learned society (except for patient organizations within the scope of Annex III of the IPHA Code) whose business address, place of incorporation or primary place of operation is in Europe or (ii) through which one or more HCPs provide services.

Methodology:

Scope: Regeneron Ireland will disclose all transfers of value made directly or indirectly to Irish HCPs or HCOs. This will include items reported by other Regeneron Pharmaceuticals Inc. entities to Regeneron Ireland.

Transfer of Value Date: The date to be used when disclosing a payment to HCPs and HCOs based on payment date. Payments made directly to the HCP or HO will reflect check or ACH date. Payments made on behalf of the HCP will reflect the date the charge was incurred. Payments falling within the reporting period covered by the report will be included on the report.

Individual and Aggregate Disclosure: Disclosure will be made on an individual basis unless consent has not been obtained from the HCP or HCO. In instances where consent has not been obtained, disclosures will be made in the aggregate.

Currency utilized: Disclosure will be made in EUR.

Identification of Transfer of Values: Regeneron Pharmaceuticals Inc., including all subsidiaries has a robust process for identification of Transfers of Values to HCPs and HCOs. This process starts with the proper classification of the vendors within Regeneron systems and flows through a detailed analysis of spend with such identified vendor types.

Categorization of Transfers of Values: The transfer of value made to a HCP or HCO will be categorized according to the items listed within the IPHA code, generally as follows:

- Donations and Grants to HCOs
- Contribution to cost of events e.g. sponsorship for registration fees, travel and accommodation, such as:
 - Congress/Meeting registration
 - Flights
 - Hotel
 - Other transportations costs (mileage, parking, public transportation)
- Fee for Service and Consultancy
 - Speaker fee
 - Advisory Boards and other consultancy engagements
 - Chairing a meeting
 - Training
 - Educational/Scientific Events
 - Market Research Participant (single blinded or unblended)
 - Related expenses agreed in the Fee for Service or consultancy contract, such as:
 - Flights
 - Hotel
 - Other transportations costs (mileage, parking, public transportation)

VAT: Disclosures will be made inclusive of VAT.